Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · TriSalus Life Sciences, Inc. (TLSI)

TriSalus Q3 revenue up 11.3% to $12.9 million; 2026 guidance revised to $46-48 million

Positive Impact 4 of 5 guidance

TriSalus Life Sciences reported third-quarter 2026 revenue of $12.9 million, up 11.3% from a year earlier, and narrowed its operating loss to $7.7 million from $9.0 million. The company revised its full-year 2026 revenue guidance to $46 million to $48 million, which it said represents growth of about 2% to 6% over 2025, and said team productivity has ramped slightly slower than anticipated.

Key points

  • Q3 2026 revenue $12.9 million, up 11.3% year over year; gross margin 86.2% vs. 83.5%
  • Net loss attributable to common stockholders $8.9 million, or $0.15 per share, vs. $41.3 million, or $0.96 per share, in Q3 2025; prior-year figure included about $30.5 million tied to a preferred stock conversion
  • Full-year 2026 revenue guidance revised to $46 million to $48 million
  • Cash and cash equivalents $41.1 million at September 30, 2026

The filing

CompanyTriSalus Life Sciences, Inc. (TLSI)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:06 AM ET
Accession number0001628280-26-072513

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.